Related Experiment Video
Updated: Apr 14, 2026
Hydra, a Computer-Based Platform for Aiding Clinicians in Cardiovascular Analysis and Diagnosis
Published on: September 26, 2018
Unlocking the Potential of Biomarkers in Varied Cardiovascular Associated Conditions with Individualized Treatment
Mridul Guleria1, Arprita Malhan1, Deepanshu Goyal2
1Department of Pharmaceutical Sciences, Guru Nanak Dev University, Amritsar, Punjab 143005, India.
Insights
Biomarkers are crucial for managing cardiovascular diseases (CVDs). New research highlights circulating biomarkers like hsCRP and troponins for personalized CVD treatment and improved patient outcomes.
Area of Science:
- Biomarker research in cardiovascular medicine.
- Personalized cardiovascular therapies.
- Nanobiotechnology and AI in cardiology.
Background:
- Cardiovascular diseases (CVDs) are a leading global cause of death.
- Biomarkers are essential for CVD prognosis, risk stratification, and management.
- Effective CVD management requires accurate diagnostic and prognostic tools.
Purpose of the Study:
- To review current biomarkers used in cardiovascular disease (CVD) treatment.
- To summarize recent clinical trial findings and advances in biomarker research.
- To explore the role of biomarkers in personalized cardiovascular medicine.
Main Methods:
- Comprehensive literature review of biomarker applications in CVD.
- Analysis of recent clinical trial data on cardiovascular biomarkers.
- Synthesis of information on emerging biomarker technologies and their clinical utility.
Main Results:
- Identified circulating biomarkers such as high-sensitivity C-reactive protein (hsCRP), cardiac troponins (cTn), and microRNAs enhance cardiovascular event prediction.
- Biomarkers are derived from inflammation, endothelial dysfunction, and myocardial infarction (MI).
- Biomarkers serve as prognostic indicators, diagnostic markers, and safety monitors.
Conclusions:
- Biomarker-guided personalized medicine offers tailored CVD treatment strategies.
- Nanobiotechnology and artificial intelligence (AI) are emerging tools for targeted CVD therapy and improved patient care.
- Further research is needed to refine biomarkers and optimize their clinical application for better cardiovascular health outcomes.
Introduction:
Biomarkers play a pivotal role in the prognosis, risk stratification, and management of cardiovascular diseases (CVDs), which remain the foremost cause of morbidity and mortality globally.
Methods:
A comprehensive review explores the various types of biomarkers utilized in the treatment of different CVD conditions, presenting the information clearly and concisely. Additionally, this overview summarizes recent clinical trial findings and advances in biomarker research.
Results:
Recent advancements in biomarker research have identified a range of circulating biomarkers, including high-sensitivity C-reactive protein (hsCRP), cardiac troponins (cTn) and various microRNAs, that enhance the predictive accuracy for cardiovascular events. These biomarkers are derived from diverse pathophysiological processes such as inflammation, endothelial dysfunction and MI.
Discussion:
As versatile tools, biomarkers serve as prognostic indicators, diagnostic markers, intermediate and surrogate endpoints, and safety monitors, making them essential in personalized medicine. In this context, biomarker-guided cardiovascular therapies represent an advanced approach, allowing clinicians to customize treatment choices and track therapeutic effectiveness in real time. In addition, nanobiotechnology-based systems are also pivotal in personalized medicine, offering targeted therapeutic delivery for CVDs, particularly in addressing heart cell death. Moreover, artificial intelligence, which is emerging as a useful tool in biomarker-guided, personalized cardiovascular treatment, is improving patient care and aiding cardiologists.
Conclusion:
Recent strides in biomarker research suggest that personalized medicine guided by circulating biomarkers could revolutionize CVD management by enhancing risk prediction and tailoring treatments to each patient. Future research should focus on refining these biomarkers and addressing current limitations to optimise their clinical utility in improving cardiovascular health outcomes.
Related Concept Videos
01:19Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers
These markers indicate stress or strain on the heart muscle:
Natriuretic Peptides (BNP)
Cardiac myocytes produce these hormones in response to ventricular stretching...
01:20Blood Studies for Cardiovascular System I: Cardiac Biomarkers
The essential diagnostic tools for detecting myocardial necrosis and monitoring individuals suspected of having acute coronary syndrome (ACS) include:
Troponins
Troponins, particularly cardiac troponins I and T, are the most precise and sensitive markers of myocardial injury. They are detectable within 4-6 hours of myocardial injury and remain...
01:18Cardiovascular Drugs: Classification based on Therapeutic Indications
01:30Coronary Artery Disease I: Introduction
01:26Atherosclerosis III: Management
01:29Pharmacogenomics: Identification of New Drug Targets